Survival After Pathological Complete Response Following Neoadjuvant Chemotherapy vs Chemoradiotherapy in Esophageal Squamous Cell Carcinoma - PubMed
5 days ago
- #Esophageal Cancer
- #Neoadjuvant Therapy
- #Survival Analysis
- Study compares survival outcomes in esophageal squamous cell carcinoma (ESCC) patients achieving pathological complete response (pCR) after neoadjuvant chemotherapy (NAC) vs. chemoradiotherapy (NACRT).
- Integrated analysis of 7 phase III trials with 1,044 patients showed higher pCR rates with NACRT (34.2%) than NAC (6.9%).
- Among pCR patients, 5-year overall survival was significantly higher with NAC (97.5%) compared to NACRT (70.4%).
- Recurrence-free survival at 5 years was also better with NAC (80.8%) vs. NACRT (63.7%).
- Multivariable analysis confirmed a survival advantage for NAC in pCR patients, suggesting potential for surgery avoidance strategies.